# Open Label, Adaptive, Parallel Group PET Study Using RO7017773 And [11C] RO15-4513

> **NCT03507569** · PHASE1 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 6 (actual)

## Conditions studied

- Autism Spectrum Disorder

## Interventions

- **DRUG:** RO7017773
- **OTHER:** [11C] Ro15-4513

## Key facts

- **NCT ID:** NCT03507569
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-04-24
- **Primary completion:** 2018-06-22
- **Final completion:** 2018-06-22
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2019-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03507569

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03507569, "Open Label, Adaptive, Parallel Group PET Study Using RO7017773 And [11C] RO15-4513". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03507569. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*